AOP-Wiki

API

All KERs

Showing 451 to 475 of 3002 KERs

ID	Upstream Event	Downstream Event	Creation Date	Last Updated	AOPs

1974	1673: Alveolar collapse	1677: Reduced tidal volume	Jul 3, 2019	Jul 3, 2019	1 AOP 302: Lung surfactant function inhibition leading to decreased lung function
2284	1673: Alveolar collapse	1498: Loss of alveolar capillary membrane integrity	Feb 16, 2021	Feb 1, 2022	1 AOP 302: Lung surfactant function inhibition leading to decreased lung function
2285	1673: Alveolar collapse	1833: Impaired lung function	Feb 16, 2021	Feb 16, 2021	None
2371	1673: Alveolar collapse	1250: Decreased lung function	Apr 27, 2021	Apr 27, 2021	1 AOP 302: Lung surfactant function inhibition leading to decreased lung function
1971	1674: Alveolar reopening	1675: Loss of barrier function	Jul 3, 2019	Jul 3, 2019	None
2173	1674: Alveolar reopening	1498: Loss of alveolar capillary membrane integrity	Oct 22, 2020	Oct 22, 2020	None
3379	2274: Androgen receptor activation, increased	286: Altered, Transcription of genes by the AR	Nov 2, 2024	Nov 24, 2024	None
3628	2274: Androgen receptor activation, increased	2365: Anogenital distance, increased	Sep 5, 2025	Sep 5, 2025	1 AOP 547: Androgen receptor agonism leading to long anogenital distance in female offspring
2983	2160: Angiogenesis disfunction	2161: Increase, Vascular disrupting effects	Aug 19, 2023	Aug 19, 2023	None
3032	2181: Angiogenesis dysfunction	2161: Increase, Vascular disrupting effects	Aug 28, 2023	Aug 28, 2023	5 AOPs 511: The AOP framework on ROS-mediated oxidative stress induced vascular disrupting effects 509: Nrf2 inhibition leading to vascular disrupting effects through activating apoptosis signal pathway and mitochondrial dysfunction 510: Demethylation of PPAR promotor leading to vascular disrupting effects 507: Nrf2 inhibition leading to vascular disrupting effects via inflammation pathway 508: Nrf2 inhibition leading to vascular disrupting effects through activating HIF1α, Semaphorin 6A, and Dll4-Notch pathway
2518	1935: Ang (1-7) levels reduced	1936: Degradation of Ang-II reduced	Oct 28, 2021	Oct 28, 2021	None
2519	1936: Degradation of Ang-II reduced	1741: Induced, Angiotensin (Ang) II accumulation	Oct 28, 2021	Oct 28, 2021	None
3645	2370: A1AR Antagonism	2371: Reduced CRF	Oct 1, 2025	Oct 9, 2025	1 AOP 604: Binding of Alpha 1-Adrenergics to Antagonists Leading to Depression
2123	26: Antagonism, Androgen receptor	1688: AGD, decreased	May 11, 2020	Aug 7, 2020	None
2130	26: Antagonism, Androgen receptor	1614: Decrease, AR activation	May 11, 2020	Mar 18, 2025	4 AOPs 306: Androgen receptor (AR) antagonism leading to short anogenital distance (AGD) in male (mammalian) offspring 344: Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring 477: Androgen receptor (AR) antagonism leading to hypospadias in male (mammalian) offspring 345: Androgen receptor (AR) antagonism leading to decreased fertility in females
2133	26: Antagonism, Androgen receptor	1786: nipple retention, increased	May 11, 2020	Sep 17, 2025	1 AOP 344: Androgen receptor (AR) antagonism leading to nipple retention (NR) in male (mammalian) offspring
2201	26: Antagonism, Androgen receptor	286: Altered, Transcription of genes by the AR	Nov 2, 2020	Feb 2, 2021	1 AOP 19: Androgen receptor antagonism leading to adverse effects in the male foetus (mammals)
3397	26: Antagonism, Androgen receptor	310: Alteration, Wnt pathway	Nov 18, 2024	Nov 18, 2024	1 AOP 19: Androgen receptor antagonism leading to adverse effects in the male foetus (mammals)
3617	26: Antagonism, Androgen receptor	2080: Impaired, blood testis barrier	Sep 3, 2025	Sep 3, 2025	1 AOP 595: Nanoplastic effect
129	112: Antagonism, Estrogen receptor	285: Reduction, Vitellogenin synthesis in liver	Nov 29, 2016	Nov 30, 2016	1 AOP 30: Estrogen receptor antagonism leading to reproductive dysfunction
2613	112: Antagonism, Estrogen receptor	1457: EMT	Mar 22, 2022	Aug 27, 2023	1 AOP 443: DNA damage and mutations leading to Metastatic Breast Cancer
3120	112: Antagonism, Estrogen receptor	2207: inhibition, EKR1/2 signaling pathway	Jan 25, 2024	Jan 25, 2024	1 AOP 522: Estrogen antagonism leading to increased risk of autism-like behavior
1061	638: Antagonism, Histamine Receptor (H2)	633: Decrease, histaminergic neuron excitation	Nov 29, 2016	Dec 3, 2016	1 AOP 99: Histamine (H2) receptor antagonism leading to reduced survival
2720	2027: Antagonism Smoothened	2028: Decrease, GLI1/2 translocation	Jul 28, 2022	Jul 28, 2022	None
2734	2027: Antagonism Smoothened	2044: Decrease, SMO relocation	Aug 23, 2022	Apr 2, 2025	1 AOP 460: Antagonism of Smoothened receptor leading to orofacial clefting

Key Event Relationships (KERs)

All KERs